Skip to main content
OpenTrials
Completed

NCT Number: NCT02195635

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

To evaluate the effect of octreotide acetate injections (200 µg 3 times daily [tid]) on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single-dose telotristat etiprate in healthy male and female subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lexicon Investigational Site

Daytona Beach, Florida, 32117, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males or females ≥18 to ≤55 years of age
  • Body mass index 18.0 to 32.0 kg/m2, inclusive, at Screening
  • Vital signs (after at least 5 minutes resting in a supine position) at Screening that are within the following ranges: Systolic blood pressure, 90 to 140 mm Hg; Diastolic blood pressure, 50 to 90 mm Hg; Heart rate 40 to 100 beats per minute (bpm)
  • Willing to adhere to the prohibitions and restrictions specified in this protocol
  • Able to comprehend and willing to sign an Informed Consent Form

Exclusion criteria

  • Presence of clinically significant physical, laboratory, or electrocardiogram (ECG) findings at Screening or Check-in (Day 1) that, in the opinion of the Investigator and/or the Sponsor or Sponsor's representative, may interfere with any aspect of study conduct or interpretation of results
  • Use of any medications (prescription or over-the-counter), herbal tea, energy drinks, herbal products (eg, St. John's Wort, garlic, milk thistle, etc.), or supplements/supratherapeutic doses of vitamins within 14 days prior to the first dose administration and throughout the duration of the study, with the exception of those approved by the Investigator and/or the Sponsor or Sponsor's representative
  • Prior exposure to telotristat etiprate
  • Use of tobacco, smoking cessation products, or products containing nicotine within 3 months prior to Screening and for the duration of the study
  • History of any major surgery within 6 months prior to Screening
  • History of renal disease
  • History of hepatic disease, or significantly abnormal liver function tests (>1.5 x upper limit of normal [ULN])
  • History of gall bladder abnormalities
  • History of any endocrine disorder
  • History of alcohol or substance abuse within 2 years prior to Screening
  • Positive urine screen for drugs of abuse and cotinine
  • Consumption of caffeine- and/or xanthine containing products (eg, cola, coffee, tea, chocolate) within 72 hours prior to Check-in
  • Consumption of alcohol within 48 hours prior to Check in
  • Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange containing products within 72 hours prior to Check in

Treatment and study plan

Telotristat etiprate

Drug

500 mg telotristat etiprate

octreotide acetate

Drug

200 µg octreotide acetate three times daily

Primary outcomes

  1. Plasma concentrations of telotristat ethyl

    Time frame: Days 1, 2, 3, 6, 7, 8

  2. Plasma concentrations of metabolite LP-778902

    Time frame: Days 1, 2, 3, 6, 7, 8

Secondary outcomes

  1. Number of treatment-emergent adverse events

    Time frame: Up to 39 days

Sponsors and collaborators

Lead sponsor

Lexicon Pharmaceuticals

Industry

Registry information

Official study title

A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Octreotide Acetate Injection (Sandostatin®) on the Pharmacokinetics of Single-dose Telotristat Etiprate in Healthy Male and Female Subjects

Important dates

Study start
2014
Primary completion
2014
First posted
Jul 21, 2014
Registry last updated
Sep 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.